This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Psoriatic Arthritis (PsA) Treatment Market

Market Insights on Psoriatic Arthritis (PsA) Treatment covering sales outlook, demand forecast & up-to-date key trends

Psoriatic Arthritis (PsA) Treatment Market by Product (Non-steroidal Anti-inflammatory Drugs, Disease Modifying Anti-rheumatic Drugs, Biologics) & Region - Forecast 2022-2028

Psoriatic Arthritis (PsA) Treatment Market Outlook – 2022-2028

[193 Pages Report] Sales in the global Psoriatic Arthritis (PsA) Treatment Market are slated to top US$ 10.3 Bn in 2022. Expanding at a healthy 7.1% CAGR, the market size is projected to total US$ 15.6 Bn by 2028.

Attribute

Details

Psoriatic Arthritis (PsA) Treatment Market Estimated Size 2022

US$ 10.3 Bn 

Psoriatic Arthritis (PsA) Treatment Market Value-based CAGR (2022-2028)

~7.1%

Psoriatic Arthritis (PsA) Treatment Market Size in Projected 2028

US$ 15.6 Bn

The increasing need to prevent various effects of psoriatic arthritis, such as nail pitting, tender joints, flaky scalp, morning stiffness, painful muscles, and swollen fingers among the geriatric population, is anticipated to bolster the market in the upcoming years. In addition, the rising prevalence of this condition amongst those patients already suffering from plaque psoriasis is set to propel the sales in this market.

Besides, the easy availability of highly effective biological medicines for psoriasis, rapid adoption of hectic lifestyles leading to the overstimulation of the immune system, and increasing number of approvals of alternative therapies for psoriatic arthritis, are estimated to boost the market in the near future. Coupled with this, the emergence of online pharmacy solutions and telehealth facilities for getting one’s medications and prescriptions delivered at home is likely to augment the market.  

Customize this Report

Let us know your requirement to get
100% FREE customization

How The Market Progressed Till June 2022?

Particulars

Details

H1, 2021

7.18%

H1, 2022 Projected

7.06%

H1, 2022 Outlook

6.86%

BPS Change - H1, 2022 (O) – H1, 2022 (P)

(-) 20 ↓

BPS Change – H1, 2022 (O) – H1, 2021

(-) 32 ↓

FMI presents a comparative analysis of the market growth rates and development scenarios in the global market. The market is influenced by several demographic and innovation factors which are subjected to the impact of macro and industry factors. Some new developments in the market include an increase in government initiatives for awareness, a growing number of drug approvals from regulatory bodies, and favourable reimbursement policies.

According to FMI analysis, the psoriatic arthritis (PsA) treatment market is projected to decline by 32 Basis Point Share (BPS) in H1- 2022 compared to H1-2021. Additionally, a BPS change of nearly 20 BPS was observed when comparing H1-2022 Outlook and H1-2022 Projected growth rate.

The key reasons for this dip in BPS are due to the high cost associated with psoriatic arthritis (PsA) treatment, and the adverse effects associated with usage of some drugs during treatment. Additionally, the availability of alternative treatments for psoriatic arthritis is also expected to hamper market growth during the forecast period.

Regardless of these negative forecasts, there are some positive aspects stay ahead for the industry which includes successive launches and constant developments of advanced products for rheumatoid psoriasis treatment.

2013-2021 Psoriatic Arthritis (PsA) Treatment Market Outlook in Comparison to 2022-2028 Growth Forecast

The psoriatic arthritis (PsA) treatment market is expected to register 7.1% CAGR between 2022 and 2028, up from 6.7% CAGR recorded during 2013-2021, predicts Future Market Insights.

The consecutive launches and consistent developments of breakthrough products for rheumatoid psoriasis treatment are anticipated to drive the market in the near future. Various pharmaceutical companies are striving to enhance the efficacy and safety of their products owing to the implementation of stringent norms by the governments of various countries.

Psoriatic Arthritis (PsA) Treatment Market Download Report Brochure

At the same time, the number of head-to-head trials between late-stage pipeline candidates, new drugs, and vital commercial products is likely to surge in the forthcoming years. This would further help in investigating the superiority of performance of numerous psoriatic medications through a comparative analysis of a large number of parameters.

Many academic and research institutions are also engaging in extensive research and development activities to unveil alternative therapies for psoriatic arthritis. For instance, in December 2021, researchers at Griffith University, Australia, found that upadacitinib has exhibited comparable safety and efficacy as monotherapy. It has also demonstrated superiority when used in combination with non-biologic disease-modifying antirheumatic drugs in patients living with psoriasis orthotics. The development of such novel treatment options by researchers and companies for psoriatic arthritis prevention is projected to support the growth in this market.

Which are the Factors Accelerating Development of Novel Psoriatic Medications?

The increasing life expectancy, genetic changes, higher prevalence of stressful lifestyles, and high geriatric population are set to propel the prevalence of psoriatic arthritis across the globe. Also, regulatory bodies in various countries are conducting awareness campaigns through social media platforms to make people better understand the importance of psoriatic arthritis prevention.

According to the World Health Organization (WHO), 1 in 6 people will be aged 60 years or above globally in 2030. In addition to this, the world’s population of people aged 60 years and older is expected to double by 2050 and reach 2.1 billion. This trend is set to continue, thereby creating new growth opportunities for pharmaceutical companies present in the field of psoriatic medications.

On top of that, psoriatic arthritis and psoriasis bone pain are often linked with depression and anxiety, which would enable companies to conduct R&D activities for coming up with new drugs. In April 2020, for instance, researchers at the Krembil Research Institute discovered that psoriatic arthritis and depression are closely related as depression can lead to inflammation and vice versa.

Patients with psoriatic arthritis have high levels of immune system proteins called cytokines that can trigger inflammation and lead to depression, whereas the inability of patients to perform their daily activities can result in depression. To prevent these conditions, various companies are expected to launch alternative therapies for psoriatic arthritis in the near future.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Country-wise Insights

What is the U.S. Psoriatic Arthritis (PsA) Treatment Market Outlook?

“Fast Track Approvals of Novel Psoriasis Orthotics Drugs to Bolster Growth”

The increasing demand for state-of-the-art psoriatic medications owing to the growing burden of the disease in the U.S. is projected to bolster the market in North America. As per the National Psoriasis Foundation, in the U.S., more than 8 million people suffer from psoriasis. In addition, if one parent has this disease, then a child has around a 10% chance of developing psoriasis. These numbers are set to continue in the forthcoming years, thereby driving the demand for psoriasis orthotics drugs.

Moreover, the rising R&D expenditure by key players, speedy approvals of biological medicines for psoriasis, and increasing government support to conduct clinical trials to discover novel treatment options for psoriatic arthritis prevention, are anticipated to boost the market in the U.S.

In December 2021, for instance, Amgen Inc., which is a reputed biopharmaceutical company based in California, bagged the U.S. FDA approval for the expanded usage of Otezla. It can now be used to treat adults with mild to moderate plaque psoriasis. The approval enabled the company to market Otezla as the only oral treatment option for adult patients. Spurred by the development of such innovative drugs for the treatment of psoriasis orthotics is likely to drive the market in the U.S.

Why is the U.K. Psoriatic Arthritis (PsA) Treatment Market Showcasing Robust Growth?

“Increasing Prevalence of Psoriasis Bone Pain to Drive the Market”

The rising cases of psoriasis bone pain among people in the U.K. is expected to augment the Europe market. To prevent such chronic effects of psoriatic arthritis, various drug manufacturers are anticipated to introduce unique treatment options in this country.

For instance, the U.K.’s National Institute for Health and Care Excellence (NICE) issued a Final Appraisal Determination (FAD) in January 2022, for recommending Rinvoq (upadacitinib) 15mg manufactured by AbbVie as a novel option for treating adult patients with active psoriatic arthritis. It can be used in combination with methotrexate or individually in these patients. Thus, the ongoing development and approval of new drugs to prevent psoriasis bone pain and other effects of psoriatic arthritis is set to accelerate the market in the U.K.

Which are the Factors Propelling China Psoriatic Arthritis (PsA) Treatment Market?

“Rising Prevalence of Obesity-induced Pustular Psoriasis Arthritis will Drive Market”

The surging prevalence of obesity is one of the crucial factors which is anticipated to drive the development of biological medicines for psoriasis in China. In December 2021, for instance, the country implemented its first guideline on physical activities, especially for citizens with chronic diseases to enhance the health of the entire population.

China's State Council had previously stated that more than 50% of adults in the country are overweight. The risk of pustular psoriasis arthritis is high in the obese population and thus the development of new drugs to prevent the severe effects of psoriatic arthritis is likely to surge in China.

The increasing smoking habit, high alcohol consumption, and adoption of unhealthy lifestyles are set to drive the market in this country. As per WHO, in 2016, in China, the total per capita consumption of alcohol was 17.0 liters among males and 6.0 liters in females. The prevalence of heavy episodic drinking was 60.8% in males and 24.9% among females above 15 years the same year. The consumption rate is expected to rise in the near future and increase the risk of pustular psoriasis arthritis among people in this country.

Category-wise Insights

Which is the Most Preferred Product in the Psoriatic Arthritis (PsA) Treatment Market?

“Patients are Preferring Non-steroidal Anti-inflammatory Drugs for Treating Psoriasis Orthotics”

Based on product, the non-steroidal anti-inflammatory drugs segment is set to dominate the psoriasis arthritis treatment market by generating the highest share in the near future. This growth is attributable to their increasing usage as an adjunct treatment in combination with disease-modifying antirheumatic drugs or biological medicines for psoriasis to cure severe cases.

Additionally, non-steroidal anti-inflammatory drugs are not recommended for patients suffering from chronic psoriasis as these can result in the occurrence of skin flare-ups. Thus, various drug manufacturing companies are anticipated to come up with new non-steroidal anti-inflammatory drugs with lesser side-effects, which would propel the segment.

Which is the Preferred Route of Administration for Psoriatic Arthritis (PsA) Treatment t?

“Injectables to Exhibit Steady Growth Backed by the Launch of Biologics for Pustular Psoriasis Arthritis”

By route of administration, the injectable segment is likely to account for 84.8% of the psoriasis arthritis treatment market share in 2022, predicts FMI. The increasing launch of biosimilars and biologics for the treatment of pustular psoriasis arthritis is anticipated to drive the growth of this segment in the forthcoming years.

Besides, injectables would help in controlling the skin involvement and inflammation in the affected joints for preventing disability and joint pain. Steroid injection is the most commonly used route of administration for rheumatoid psoriasis treatment.   

Which is the Dominant Distribution Channel in the Psoriatic Arthritis (PsA) Treatment Market?

“Hospital Pharmacies are Highly Preferred for Rheumatoid Psoriasis Treatment”

In terms of distribution channel, the hospital pharmacies segment is estimated to remain in the forefront in the psoriasis arthritis treatment market through 2028. The increasing number of hospitals across the globe is projected to drive this segment.

Furthermore, the availability of technologically advanced healthcare devices and medications in hospital pharmacies is surging their preference among patients for the management of critical conditions, such as rheumatoid psoriasis treatment. At the same time, the presence of skilled healthcare providers in these pharmacies is expected to drive the segment’s growth.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Competition Landscape

Key players operating in the market are striving to offer alternative therapies for psoriatic arthritis to cater to the high unmet needs. Some of the other players are collaborating with various government agencies to create awareness about psoriatic arthritis prevention among the general public. A few others are engaging in joint ventures, acquisitions, mergers, and collaborations to co-develop novel treatment options and gain fast track approval from the regulatory bodies.

For instance,

  • In December 2021, Novartis, a multinational pharmaceutical corporation based in Switzerland, received the US Food and Drug Administration (FDA) approval for Cosentyx (secukinumab). It will be used for the treatment of active psoriatic arthritis in patients belonging to the age group of two years and older, as well as enthesitis-related arthritis in patients four years and older. Cosentyx is considered to be the only biologic treatment approved by the FDA for the treatment of both active psoriatic and enthesitis-related arthritis in pediatric patients across the U.S.
  • In December 2021, AbbVie, a leading biopharmaceutical company headquartered in Illinois, bagged the U.S. FDA approval for Rinvoq for the treatment of psoriatic arthritis in adult patients who have failed at least one Tumor Necrosis Factor (TNF) inhibitor. The drug has proved to be a powerful treatment for the condition and this approval will help the company to strengthen its position in the market.

Scope of Report

Attribute

Details

Forecast Period

2013-2021

Historical Data Available for

2022-2028

Market Analysis

Units for Volume and US$ Bn for Value

Key Regions Covered

North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa.

Key Countries Covered

United States, Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Russia, Poland, China, India, Thailand, Indonesia, Australia and New Zealand, Japan, GCC countries, North Africa, South Africa, others.

Key Market Segments Covered

Product, Route of Administration, Distribution Channel, and Region

Key Companies Profiled

  • Pfizer Inc.
  • Johnson & Johnson
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • UCB S.A.
  • Eli Lilly & Co
  • Novartis AG
  • Celgene Corporation
  • AstraZeneca PLC

Pricing

Available upon Request

Psoriatic Arthritis (PsA) Treatment Market by Category

Product Type:

  • Non-steroidal Anti-inflammatory Drugs
  • Disease Modifying Anti-rheumatic Drugs
    • Corticosteroids
    • Antimalarial
    • Methotrexate
    • Others
  • Biologics
    • TNF Inhibitors
    • Interleukin Inhibitors

Route of Administration:

  • Injectable
  • Oral

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies

Region:        

  • North America
  • Latin America
  • Europe
  • Oceania
  • East Asia
  • South Asia
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global Psoriatic Arthritis (PsA) treatment market is expected to reach a valuation of US$ 10.3 Bn in 2022.

The global Psoriatic Arthritis (PsA) treatment market grew at a healthy 6.7% CAGR between 2013 and 2021.

The increasing cases of obesity and the rising development of new treatment options are the key trends boosting the sales of drugs for Psoriatic Arthritis (PsA) treatment.

Pfizer Inc., Johnson & Johnson, AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, UCB S.A., Eli Lilly & Co, Novartis AG, Celgene Corporation, and AstraZeneca PLC are some of the leading players present in the global Psoriatic Arthritis (PsA) treatment market.

The oral route of administration is anticipated to account for 15.2% of the Psoriatic Arthritis (PsA) treatment market share in 2022.

The injectable route of administration is projected to account for 84.8% of the Psoriatic Arthritis (PsA) treatment market share in the forecast period.

Table of Content

1. Executive Summary

    1.1. Market Overview

    1.2. Market Analysis

    1.3. FMI Analysis and Recommendations

    1.4. Wheel of Fortune

2. Market Introduction

    2.1. Market Taxonomy

    2.2. Market Definition

3. Global Psoriatic Arthritis Treatment Market Opportunity Analysis

    3.1. Macro-Economic Factors

    3.2. Opportunity Analysis

4. Market Background

    4.1. Market Dynamics

        4.1.1. Drivers

        4.1.2. Restraints

        4.1.3. Trends

5. Key Inclusions

    5.1. Regulatory Scenario

    5.2. Pipeline Analysis

6. North America Psoriatic Arthritis Treatment Market Analysis 2013-2021 and Forecast 2022-2028

    6.1. Introduction

    6.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021

        6.2.1. U.S.

        6.2.2. Canada

    6.3. Market Size (US$ Mn) Forecast By Country, 2022-2028

    6.4. Historical Market Size (US$ Mn) Analysis By Product Type, 2013-2021

        6.4.1. Nonsteriodal Anti-inflammatory Drugs

        6.4.2. Disease Modifying Antirheumatic Drugs

            6.4.2.1. Corticosteriods

            6.4.2.2. Antimalarials

            6.4.2.3. Methotrexate

            6.4.2.4. Others

        6.4.3. Biologics

            6.4.3.1. TNF Inhibitors

            6.4.3.2. Interleukin Inhibitors

    6.5. Market Size (US$ Mn) Forecast By Product Type, 2022-2028

    6.6. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2013-2021

        6.6.1. Oral

        6.6.2. Injectable

    6.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

    6.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        6.8.1. Hospital Pharmacies

        6.8.2. Retail Pharmacies

        6.8.3. Mail Order Pharmacies

    6.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    6.10. Market Attractiveness Analysis

        6.10.1. By Country

        6.10.2. By Product Type

        6.10.3. By Route of Administration

        6.10.4. By Distribution Channel

    6.11. Drivers and Restraints: Impact Analysis

7. Latin America Psoriatic Arthritis Treatment Market Analysis 2013-2021 and Forecast 2022-2028

    7.1. Introduction

    7.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021

        7.2.1. Brazil

        7.2.2. Mexico

        7.2.3. Rest of Latin America

    7.3. Market Size (US$ Mn) Forecast By Country, 2022-2028

    7.4. Historical Market Size (US$ Mn) Analysis By Product Type, 2013-2021

        7.4.1. Nonsteriodal Anti-inflammatory Drugs

        7.4.2. Disease Modifying Antirheumatic Drugs

            7.4.2.1. Corticosteriods

            7.4.2.2. Antimalarials

            7.4.2.3. Methotrexate

            7.4.2.4. Others

        7.4.3. Biologics

            7.4.3.1. TNF Inhibitors

            7.4.3.2. Interleukin Inhibitors

    7.5. Market Size (US$ Mn) Forecast By Product Type, 2022-2028

    7.6. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2013-2021

        7.6.1. Oral

        7.6.2. Injectable

    7.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

    7.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        7.8.1. Hospital Pharmacies

        7.8.2. Retail Pharmacies

        7.8.3. Mail Order Pharmacies

    7.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    7.10. Market Attractiveness Analysis

        7.10.1. By Country

        7.10.2. By Product Type

        7.10.3. By Route of Administration

        7.10.4. By Distribution Channel

    7.11. Drivers and Restraints: Impact Analysis

8. Europe Psoriatic Arthritis Treatment Market Analysis 2013-2021 and Forecast 2022-2028

    8.1. Introduction

    8.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021

        8.2.1. U.K.

        8.2.2. France

        8.2.3. Italy

        8.2.4. Spain

        8.2.5. Russia

        8.2.6. Germany

        8.2.7. Rest of Europe

    8.3. Market Size (US$ Mn) Forecast By Country, 2022-2028

    8.4. Historical Market Size (US$ Mn) Analysis By Product Type, 2013-2021

        8.4.1. Nonsteriodal Anti-inflammatory Drugs

        8.4.2. Disease Modifying Antirheumatic Drugs

            8.4.2.1. Corticosteriods

            8.4.2.2. Antimalarials

            8.4.2.3. Methotrexate

            8.4.2.4. Others

        8.4.3. Biologics

            8.4.3.1. TNF Inhibitors

            8.4.3.2. Interleukin Inhibitors

    8.5. Market Size (US$ Mn) Forecast By Product Type, 2022-2028

    8.6. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2013-2021

        8.6.1. Oral

        8.6.2. Injectable

    8.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

    8.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        8.8.1. Hospital Pharmacies

        8.8.2. Retail Pharmacies

        8.8.3. Mail Order Pharmacies

    8.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    8.10. Market Attractiveness Analysis

        8.10.1. By Country

        8.10.2. By Product Type

        8.10.3. By Route of Administration

        8.10.4. By Distribution Channel

    8.11. Drivers and Restraints: Impact Analysis

9. Asia-Pacific Psoriatic Arthritis Treatment Market Analysis 2013-2021 and Forecast 2022-2028

    9.1. Introduction

    9.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021

        9.2.1. Japan

        9.2.2. China

        9.2.3. India

        9.2.4. Australia

        9.2.5. Rest of APAC

    9.3. Market Size (US$ Mn) Forecast By Country, 2022-2028

    9.4. Historical Market Size (US$ Mn) Analysis By Product Type, 2013-2021

        9.4.1. Nonsteriodal Anti-inflammatory Drugs

        9.4.2. Disease Modifying Antirheumatic Drugs

            9.4.2.1. Corticosteriods

            9.4.2.2. Antimalarials

            9.4.2.3. Methotrexate

            9.4.2.4. Others

        9.4.3. Biologics

            9.4.3.1. TNF Inhibitors

            9.4.3.2. Interleukin Inhibitors

    9.5. Market Size (US$ Mn) Forecast By Product Type, 2022-2028

    9.6. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2013-2021

        9.6.1. Oral

        9.6.2. Injectable

    9.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

    9.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        9.8.1. Hospital Pharmacies

        9.8.2. Retail Pharmacies

        9.8.3. Mail Order Pharmacies

    9.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    9.10. Market Attractiveness Analysis

        9.10.1. By Country

        9.10.2. By Product Type

        9.10.3. By Route of Administration

        9.10.4. By Distribution Channel

    9.11. Drivers and Restraints: Impact Analysis

10. Middle East and Africa Psoriatic Arthritis Treatment Market Analysis 2013-2021 and Forecast 2022-2028

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021

        10.2.1. GCC Countries

        10.2.2. South Africa

        10.2.3. Rest of MEA

    10.3. Market Size (US$ Mn) Forecast By Country, 2022-2028

    10.4. Historical Market Size (US$ Mn) Analysis By Product Type, 2013-2021

        10.4.1. Nonsteriodal Anti-inflammatory Drugs

        10.4.2. Disease Modifying Antirheumatic Drugs

            10.4.2.1. Corticosteriods

            10.4.2.2. Antimalarials

            10.4.2.3. Methotrexate

            10.4.2.4. Others

        10.4.3. Biologics

            10.4.3.1. TNF Inhibitors

            10.4.3.2. Interleukin Inhibitors

    10.5. Market Size (US$ Mn) Forecast By Product Type, 2022-2028

    10.6. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2013-2021

        10.6.1. Oral

        10.6.2. Injectable

    10.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

    10.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        10.8.1. Hospital Pharmacies

        10.8.2. Retail Pharmacies

        10.8.3. Mail Order Pharmacies

    10.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    10.10. Market Attractiveness Analysis

        10.10.1. By Country

        10.10.2. By Product Type

        10.10.3. By Route of Administration

        10.10.4. By Distribution Channel

    10.11. Drivers and Restraints: Impact Analysis

11. Forecast Factors: Relevance and Impact

12. Forecast Assumptions

13. Competition Analysis

    13.1. Competition Dashboard

    13.2. Competitors Deep Dive

        13.2.1. Pfizer Inc.

            13.2.1.1. Overview

            13.2.1.2. Product Portfolio

            13.2.1.3. Production Footprint

            13.2.1.4. Sales Footprint

            13.2.1.5. Channel Footprint

            13.2.1.6. Strategy

                13.2.1.6.1. Marketing Strategy

                13.2.1.6.2. Product Strategy

                13.2.1.6.3. Channel Strategy

        13.2.2. Johnson & Johnson Services, Inc.

            13.2.2.1. Product Portfolio

            13.2.2.2. Production Footprint

            13.2.2.3. Sales Footprint

            13.2.2.4. Channel Footprint

            13.2.2.5. Strategy

                13.2.2.5.1. Marketing Strategy

                13.2.2.5.2. Product Strategy

                13.2.2.5.3. Channel Strategy

        13.2.3. AbbVie Inc.

            13.2.3.1. Overview

            13.2.3.2. Product Portfolio

            13.2.3.3. Production Footprint

            13.2.3.4. Sales Footprint

            13.2.3.5. Channel Footprint

            13.2.3.6. Strategy

                13.2.3.6.1. Marketing Strategy

                13.2.3.6.2. Product Strategy

                13.2.3.6.3. Channel Strategy

        13.2.4. Amgen Inc.

            13.2.4.1. Overview

            13.2.4.2. Product Portfolio

            13.2.4.3. Production Footprint

            13.2.4.4. Sales Footprint

            13.2.4.5. Channel Footprint

            13.2.4.6. Strategy

                13.2.4.6.1. Marketing Strategy

                13.2.4.6.2. Product Strategy

                13.2.4.6.3. Channel Strategy

        13.2.5. Bristol-Myers Squibb Company

            13.2.5.1. Overview

            13.2.5.2. Product Portfolio

            13.2.5.3. Production Footprint

            13.2.5.4. Sales Footprint

            13.2.5.5. Channel Footprint

            13.2.5.6. Strategy

                13.2.5.6.1. Marketing Strategy

                13.2.5.6.2. Product Strategy

                13.2.5.6.3. Channel Strategy

        13.2.6. UCB S.A.

            13.2.6.1. Overview

            13.2.6.2. Product Portfolio

            13.2.6.3. Production Footprint

            13.2.6.4. Sales Footprint

            13.2.6.5. Channel Footprint

            13.2.6.6. Strategy

                13.2.6.6.1. Marketing Strategy

                13.2.6.6.2. Product Strategy

                13.2.6.6.3. Channel Strategy

        13.2.7. Eli Lilly & Co

            13.2.7.1. Overview

            13.2.7.2. Product Portfolio

            13.2.7.3. Production Footprint

            13.2.7.4. Sales Footprint

            13.2.7.5. Channel Footprint

            13.2.7.6. Strategy

                13.2.7.6.1. Marketing Strategy

                13.2.7.6.2. Product Strategy

                13.2.7.6.3. Channel Strategy

        13.2.8. Novartis AG

            13.2.8.1. Overview

            13.2.8.2. Product Portfolio

            13.2.8.3. Production Footprint

            13.2.8.4. Sales Footprint

            13.2.8.5. Channel Footprint

            13.2.8.6. Strategy

                13.2.8.6.1. Marketing Strategy

                13.2.8.6.2. Product Strategy

                13.2.8.6.3. Channel Strategy

        13.2.9. Celgene Corporation

            13.2.9.1. Overview

            13.2.9.2. Product Portfolio

            13.2.9.3. Production Footprint

            13.2.9.4. Sales Footprint

            13.2.9.5. Channel Footprint

            13.2.9.6. Strategy

                13.2.9.6.1. Marketing Strategy

                13.2.9.6.2. Product Strategy

                13.2.9.6.3. Channel Strategy

        13.2.10. AstraZeneca PLC

            13.2.10.1. Overview

            13.2.10.2. Product Portfolio

            13.2.10.3. Production Footprint

            13.2.10.4. Sales Footprint

            13.2.10.5. Channel Footprint

            13.2.10.6. Strategy

                13.2.10.6.1. Marketing Strategy

                13.2.10.6.2. Product Strategy

                13.2.10.6.3. Channel Strategy

14. Global Psoriatic Arthritis Treatment Market Analysis 2013-2021 and Forecast 2022-2028 By Region

    14.1. Introduction / Key Findings

    14.2. Historical Market Size (US$ Mn) Analysis By Region

        14.2.1. North America

        14.2.2. Europe

        14.2.3. Latin America

        14.2.4. Asia Pacific

        14.2.5. Middle East and Africa

    14.3. Market Size (US$ Mn) Forecast By Region

    14.4. Market Attractiveness Analysis By Region

15. Global Psoriatic Arthritis Treatment Market Analysis 2013-2021 and Forecast 2022-2028, By Product Type

    15.1. Introduction/Key Finding

    15.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2013-2021

        15.2.1. Nonsteriodal Anti-inflammatory Drugs

        15.2.2. Disease Modifying Antirheumatic Drugs

            15.2.2.1. Corticosteriods

            15.2.2.2. Antimalarials

            15.2.2.3. Methotrexate

            15.2.2.4. Others

        15.2.3. Biologics

            15.2.3.1. TNF Inhibitors

            15.2.3.2. Interleukin Inhibitors

    15.3. Market Size (US$ Mn) Forecast By Product Type, 2022-2028

    15.4. Market Attractiveness Analysis By Product Type

16. Global Psoriatic Arthritis Treatment Market Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration

    16.1. Introduction/Key Finding

    16.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2013-2021

        16.2.1. Oral

        16.2.2. Injectable

    16.3. Market Size (US$ Mn) Forecast By Product Type, 2022-2028

    16.4. Market Attractiveness Analysis By Product Type

17. Global Psoriatic Arthritis Treatment Market Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

    17.1. Introduction/Key Finding

    17.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013-2021

        17.2.1. Hospital Pharmacies

        17.2.2. Retail Pharmacies

        17.2.3. Mail Order Pharmacies

    17.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    17.4. Market Attractiveness Analysis By Distribution Channel

18. Global Psoriatic Arthritis Treatment Market Analysis 2013-2021 and Forecast 2022-2028

    18.1. Market Value Share Analysis By All Segment

    18.2. Y-o-Y Growth Analysis By All Segment

    18.3. Absolute $ Opportunity

19. Assumptions and Acronyms Used

20. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: North America Psoriatic Arthritis Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Country

Table 2: North America Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, Product Type

Table 3: North America Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Route of Administration

Table 4: North America Psoriatic Arthritis Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 5: Latin America Psoriatic Arthritis Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Country

Table 6: Latin America Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, Product Type

Table 7: Latin America Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Route of Administration

Table 8: Latin America Psoriatic Arthritis Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 9: Europe Psoriatic Arthritis Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Country

Table 10:Europe Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, Product Type

Table 11:Europe Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Route of Administration

Table 12:Europe Psoriatic Arthritis Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 13:Asia Pacific Psoriatic Arthritis Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Country

Table 14:Asia Pacific Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, Product Type

Table 15:Asia Pacific Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Route of Administration

Table 16:Asia Pacific Psoriatic Arthritis Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 17:Middle East & Africa Psoriatic Arthritis Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Country

Table 18:Middle East & Africa Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, Product Type

Table 19:Middle East & Africa Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Route of Administration

Table 20:Middle East & Africa Psoriatic Arthritis Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 21:Global Psoriatic Arthritis Treatment Market Size (US$ Mn) Forecast By Region, 2012–2021

Table 22:Global Psoriatic Arthritis Treatment Market Size Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Product Type

Table 23:Global Psoriatic Arthritis Treatment Market Size Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Route of Administration

Table 24:Global Psoriatic Arthritis Treatment Market size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Psoriatic Arthritis Treatment Market Value Share By Product Type (2018E)

Figure 02: Global Psoriatic Arthritis Treatment Market Value Share By Route of Administration (2018E)

Figure 03: Global Psoriatic Arthritis Treatment Market Value Share By Distribution Channel (2018E)

Figure 04: Global Psoriatic Arthritis Treatment Market Value Share By Region (2018E)

Figure 05: North America Psoriatic Arthritis Treatment Market Value Share By Product Type (2018E)

Figure 06: North America Psoriatic Arthritis Treatment Market Value Share By Route of Administration (2018E)

Figure 07: North America Psoriatic Arthritis Treatment Market Value Share By Distribution Channel (2018E)

Figure 08: North America Psoriatic Arthritis Treatment Market Value Share By Country (2018E)

Figure 09: North America Psoriatic Arthritis Treatment Market Size Analysis, 2013–2021

Figure 10: North America Psoriatic Arthritis Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure 11: U.S. Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 12: U.S. Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 13: Canada Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 14: Canada Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 15: North America Nonsteroidal Anti-Inflammatory Drugs Market Size (US$ Mn) Analysis, 2013–2021

Figure 16: North America Nonsteroidal Anti-Inflammatory Drugs Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 17: North America Disease-Modifying Antirheumatic Drugs (DMARDs) Market Size (US$ Mn) Analysis, 2013–2021

Figure 18: North America Disease-Modifying Antirheumatic Drugs (DMARDs) Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 19: North America Biologics Market Size (US$ Mn) Analysis, 2013–2021

Figure 20: North America Biologics Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 21: North America Psoriatic Arthritis Treatment Market Attractiveness Analysis By Product Type, 2022–2028

Figure 22: North America Psoriatic Arthritis Treatment Market Attractiveness Analysis By Route of Administration, 2022–2028

Figure 23: North America Psoriatic Arthritis Treatment Market Attractiveness Analysis By Distribution Channel, 2022–2028

Figure 24: North America Psoriatic Arthritis Treatment Market Attractiveness Analysis By Country, 2022–2028

Figure 25: Latin America Psoriatic Arthritis Treatment Market Value Share By Product Type (2018E)

Figure 26: Latin America Psoriatic Arthritis Treatment Market Value Share By Route of Administration (2018E)

Figure 27: Latin America Psoriatic Arthritis Treatment Market Value Share By Distribution Channel (2018E)

Figure 28: Latin America Psoriatic Arthritis Treatment Market Value Share By Country (2018E)

Figure 29: Latin America Psoriatic Arthritis Treatment Market Size Analysis, 2013–2021

Figure 30: Latin America Psoriatic Arthritis Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure 31: Mexico Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 32: Mexico Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 33: Brazil Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 34: Brazil Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 35: Rest of Latin America Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 36: Rest of Latin America Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 37: Latin America Nonsteroidal Anti-Inflammatory Drugs Market Size (US$ Mn) Analysis, 2013–2021

Figure 38: Latin America Nonsteroidal Anti-Inflammatory Drugs Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 39: Latin America Disease-Modifying Antirheumatic Drugs (DMARDs) Market Size (US$ Mn) Analysis, 2013–2021

Figure 40: Latin America Disease-Modifying Antirheumatic Drugs (DMARDs) Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 41: Latin America Biologics Market Size (US$ Mn) Analysis, 2013–2021

Figure 42: Latin America Biologics Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 43: Latin America Psoriatic Arthritis Treatment Market Attractiveness Analysis By Product Type, 2022–2028

Figure 44: Latin America Psoriatic Arthritis Treatment Market Attractiveness Analysis By Route of Administration, 2022–2028

Figure 45: Latin America Psoriatic Arthritis Treatment Market Attractiveness Analysis By Distribution Channel, 2022–2028

Figure 46: Latin America Psoriatic Arthritis Treatment Market Attractiveness Analysis By Country, 2022–2028

Figure 47: Europe Psoriatic Arthritis Treatment Market Value Share By Product Type (2018E)

Figure 48: Europe Psoriatic Arthritis Treatment Market Value Share By Route of Administration (2018E)

Figure 49: Europe Psoriatic Arthritis Treatment Market Value Share By Distribution Channel (2018E)

Figure 50: Europe Psoriatic Arthritis Treatment Market Value Share By Country (2018E)

Figure 51: Europe Psoriatic Arthritis Treatment Market Size Analysis, 2013–2021

Figure 52: Europe Psoriatic Arthritis Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure 53: U.K. Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 54: U.K. Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 55: France Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 56: France Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 57: Italy Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 58: Italy Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 59: Spain Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 60: Spain Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 61: Russia Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 62: Russia Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 63: Germany Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 64: Germany Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 65: Rest of Europe Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 66: Rest of Europe Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 67: Europe Nonsteroidal Anti-Inflammatory Drugs Market Size (US$ Mn) Analysis, 2013–2021

Figure 68: Europe Nonsteroidal Anti-Inflammatory Drugs Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 69: Europe Disease-Modifying Antirheumatic Drugs (DMARDs) Market Size (US$ Mn) Analysis, 2013–2021

Figure 70: Europe Disease-Modifying Antirheumatic Drugs (DMARDs) Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 71: Europe Biologics Market Size (US$ Mn) Analysis, 2013–2021

Figure 72: Europe Biologics Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 73: Europe Psoriatic Arthritis Treatment Market Attractiveness Analysis By Product Type, 2022–2028

Figure 74: Europe Psoriatic Arthritis Treatment Market Attractiveness Analysis By Route of Administration, 2022–2028

Figure 75: Europe Psoriatic Arthritis Treatment Market Attractiveness Analysis By Distribution Channel, 2022–2028

Figure 76: Europe Psoriatic Arthritis Treatment Market Attractiveness Analysis By Country, 2022–2028

Figure 77: Asia Pacific Psoriatic Arthritis Treatment Market Value Share By Product Type (2018E)

Figure 78: Asia Pacific Psoriatic Arthritis Treatment Market Value Share By Route of Administration (2018E)

Figure 79: Asia Pacific Psoriatic Arthritis Treatment Market Value Share By Distribution Channel (2018E)

Figure 80: Asia Pacific Psoriatic Arthritis Treatment Market Value Share By Country (2018E)

Figure 81: Asia Pacific Psoriatic Arthritis Treatment Market Size Analysis, 2013–2021

Figure 82: Asia Pacific Psoriatic Arthritis Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure 83: Japan Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 84: Japan Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 85: China Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 86: China Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 87: India Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 88: India Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 89: Australia Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 90: Australia Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 91: Rest of Asia Pacific Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 92: Rest of Asia Pacific Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 93: Asia Pacific Nonsteroidal Anti-Inflammatory Drugs Market Size (US$ Mn) Analysis, 2013–2021

Figure 94: Asia Pacific Nonsteroidal Anti-Inflammatory Drugs Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 95: Asia Pacific Disease-Modifying Antirheumatic Drugs (DMARDs) Market Size (US$ Mn) Analysis, 2013–2021

Figure 96: Asia Pacific Disease-Modifying Antirheumatic Drugs (DMARDs) Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 97: Asia Pacific Biologics Market Size (US$ Mn) Analysis, 2013–2021

Figure 98: Asia Pacific Biologics Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 99: Asia Pacific Psoriatic Arthritis Treatment Market Attractiveness Analysis By Product Type, 2022–2028

Figure 100:Asia Pacific Psoriatic Arthritis Treatment Market Attractiveness Analysis By Route of Administration, 2022–2028

Figure 101:Asia Pacific Psoriatic Arthritis Treatment Market Attractiveness Analysis By Distribution Channel, 2022–2028

Figure 102:Asia Pacific Psoriatic Arthritis Treatment Market Attractiveness Analysis By Country, 2022–2028

Figure 103:Middle East & Africa Psoriatic Arthritis Treatment Market Value Share By Product Type (2018E)

Figure 104:Middle East & Africa Psoriatic Arthritis Treatment Market Value Share By Route of Administration (2018E)

Figure 105:Middle East & Africa Psoriatic Arthritis Treatment Market Value Share By Distribution Channel (2018E)

Figure 106:Middle East & Africa Psoriatic Arthritis Treatment Market Value Share By Country (2018E)

Figure 107:Middle East & Africa Psoriatic Arthritis Treatment Market Size Analysis, 2013–2021

Figure 108:Middle East & Africa Psoriatic Arthritis Treatment Market Forecast & Y-o-Y growth, 2022–2028

Figure 109:South Africa Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 110:South Africa Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 111:GCC Countries Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 112:GCC Countries Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 113:Rest of Middle East & Africa Psoriatic Arthritis Treatment Market Size (US$ Mn) Analysis, 2013–2021

Figure 114:Rest of Middle East & Africa Psoriatic Arthritis Treatment Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 115:Middle East & Africa Nonsteroidal Anti-Inflammatory Drugs Market Size (US$ Mn) Analysis, 2013–2021

Figure 116:Middle East & Africa Nonsteroidal Anti-Inflammatory Drugs Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 117:Middle East & Africa Disease-Modifying Antirheumatic Drugs (DMARDs) Market Size (US$ Mn) Analysis, 2013–2021

Figure 118:Middle East & Africa Disease-Modifying Antirheumatic Drugs (DMARDs) Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 119:Middle East & Africa Biologics Market Size (US$ Mn) Analysis, 2013–2021

Figure 120:Middle East & Africa Biologics Market Forecast & Y-o-Y Growth (%), 2021-2028

Figure 121:Middle East & Africa Psoriatic Arthritis Treatment Market Attractiveness Analysis By Product Type, 2022–2028

Figure 122:Middle East & Africa Psoriatic Arthritis Treatment Market Attractiveness Analysis By Route of Administration, 2022–2028

Figure 123:Middle East & Africa Psoriatic Arthritis Treatment Market Attractiveness Analysis By Distribution Channel, 2022–2028

Figure 124:Middle East & Africa Psoriatic Arthritis Treatment Market Attractiveness Analysis By Country, 2022–2028

Figure 125:Global Psoriatic Arthritis Treatment Market Share Analysis (%) By Region, 2022 & 2028

Figure 126:Global Psoriatic Arthritis Treatment Market Y-o-Y Growth (%) By Region, 2022–2028

Figure 127:Global Psoriatic Arthritis Treatment Market Attractiveness Analysis By Region, 2022–2028

Figure 128:Global Psoriatic Arthritis Treatment Market Share Analysis (%) By Product Type, 2022 & 2028

Figure 129:Global Psoriatic Arthritis Treatment Market Y-o-Y Growth (%) By Product Type, 2022–2028

Figure 130:Global Psoriatic Arthritis Treatment Market Attractiveness Analysis By Product Type, 2022–2028

Figure 131:Global Psoriatic Arthritis Treatment Market Share Analysis (%) By Route of Administration , 2022 & 2028

Figure 132:Global Psoriatic Arthritis Treatment Market Y-o-Y Growth (%) By Route of Administration , 2022–2028

Figure 133:Global Psoriatic Arthritis Treatment Market Attractiveness Analysis By Route of Administration , 2022–2028

Figure 134:Global Psoriatic Arthritis Treatment Market Share Analysis (%) By Distribution Channel, 2022 & 2028

Figure 135:Global Psoriatic Arthritis Treatment Market Y-o-Y Growth (%) By Distribution Channel, 2022–2028

Figure 136:Global Psoriatic Arthritis Treatment Market Attractiveness Analysis By Distribution Channel, 2022–2028

Figure 137:Global Psoriatic Arthritis Treatment Market Value Analysis and Forecast, 2021–2028 (US$ Mn)

Figure 138:Global Psoriatic Arthritis Treatment Market Absolute $ Opportunity (US$ Mn), 2021–2028

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Juvenile Idiopathic Arthritis Diagnostic Market

Published : January 2019

Healthcare

Reactive Arthritis Treatment Market

Published : September 2017

Healthcare

Canine Arthritis Treatment Market

Published : October 2019

Healthcare

Rheumatoid Arthritis Treatment Market

Published : March 2017

Google translate

Psoriatic Arthritis (PsA) Treatment Market